Literature DB >> 35015924

Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants.

Nicholas W Lange1, David M Salerno1, Douglas L Jennings1, Jason Choe1, Jessica Hedvat1, Danielle Bley Kovac1, Jenna Scheffert1, Tara Shertel1, Lloyd E Ratner2, Robert S Brown3, Marcus R Pereira4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35015924     DOI： 10.1111/ajt.16955

Source DB:  PubMed          Journal:  Am J Transplant        ISSN： 1600-6135            Impact factor:   9.369


× No keyword cloud information.
  17 in total

1.  Molecular Interactions of Tannic Acid with Proteins Associated with SARS-CoV-2 Infectivity.

Authors:  Mohamed Haddad; Roger Gaudreault; Gabriel Sasseville; Phuong Trang Nguyen; Hannah Wiebe; Theo Van De Ven; Steve Bourgault; Normand Mousseau; Charles Ramassamy
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

Review 2.  Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week.

Authors:  Sonu Abraham; Anju Nohria; Tomas G Neilan; Aarti Asnani; Anu Mariam Saji; Jui Shah; Tara Lech; Jason Grossman; George M Abraham; Daniel P McQuillen; David T Martin; Paul E Sax; Sourbha S Dani; Sarju Ganatra
Journal:  J Am Coll Cardiol       Date:  2022-10-06       Impact factor: 27.203

3.  Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal.

Authors:  Dusten T Rose; Saurin M Gandhi; Rachael A Bedard; Kristin E Mondy; Alexander L Chu; Kelly C Gamble; Amanda T Gee; Monica A Kundra; Amber L Williams; Brian K Lee
Journal:  Open Forum Infect Dis       Date:  2022-05-13       Impact factor: 4.423

4.  Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series.

Authors:  Sara R Vazquez; Aaron S Wilson; Daniel M Witt
Journal:  J Thromb Thrombolysis       Date:  2022-10-18       Impact factor: 5.221

5.  Comparative evaluation of authorized drugs for treating Covid-19 patients.

Authors:  Towhidul Islam; Moynul Hasan; Mohammad Saydur Rahman; Md Rabiul Islam
Journal:  Health Sci Rep       Date:  2022-06-13

Review 6.  A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021.

Authors:  Gizem Kayki-Mutlu; Zinnet Sevval Aksoyalp; Leszek Wojnowski; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-11       Impact factor: 3.195

Review 7.  Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes.

Authors:  Francesco Nappi; Adelaide Iervolino; Sanjeet Singh Avtaar Singh
Journal:  Biomedicines       Date:  2022-02-14

8.  Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients.

Authors:  Aileen X Wang; Alan Koff; Diana Hao; Natascha M Tuznik; Yihung Huang
Journal:  Am J Transplant       Date:  2022-02-23       Impact factor: 9.369

Review 9.  Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.

Authors:  Catia Marzolini; Daniel R Kuritzkes; Fiona Marra; Alison Boyle; Sara Gibbons; Charles Flexner; Anton Pozniak; Marta Boffito; Laura Waters; David Burger; David J Back; Saye Khoo
Journal:  Clin Pharmacol Ther       Date:  2022-05-14       Impact factor: 6.903

10.  Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.

Authors:  David M Salerno; Douglas L Jennings; Nicholas W Lange; Danielle Bley Kovac; Tara Shertel; Justin K Chen; Jessica Hedvat; Jenna Scheffert; Robert S Brown; Marcus R Pereira
Journal:  Am J Transplant       Date:  2022-03-21       Impact factor: 9.369
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.